Pharma Innovation And NHS Dodge Axe In U.K. Spending Review, But There Is A Price To Pay
This article was originally published in The Pink Sheet Daily
Executive Summary
Science R&D spending will be maintained at current levels but amount to be allocated for pharmaceuticals unclear.
You may also be interested in...
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
NICE Likely To Lose Cost-Watchdog Status By 2013
A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.